2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5418 Lorlatinib in relapsed/refractory ALK-positive lymphoma after prior ALK tyrosine kinase inhibitors failure: Final Results of a prospective phase II study

Andrea Aroldi, MD, Federica Cocito, MD2, Federica Colombo, MD3, Alessia Ripamonti, MD4, Elisa Bossi, MD5, Giovanni Rindone, MD6, Luisa Verga, MD7, Fabrizio Cavalca, MD8, Beatrice Manghisi, MD9, Alberto Rapella, MD10, Stefano Bonfanti, MD11, Bianca Maria Granelli, MD12, Edoardo Scomazzon, MD13, Fabio Pagni, MD14, Vincenzo L'Imperio, MD15, Lavinia Monaco, MD16, Luca Guerra, MD17, Lara Mussolin, PhD18, Daniele Ramazzotti, PhD19, Roberto Chiarle, MD20, Luca Mologni, PhD21, Rocco Piazza, MD, PhD22, Carlo Gambacorti-Passerini, MD23
1 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
2 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
3 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
4 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
5 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
6 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
7 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
8 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
9 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
10 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
11 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Milano-Bicocca, Monza, Italy
12 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
13 San Bortolo Hospital, Vicenza, Italy
14 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
15 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
16 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
17 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
18 Città della Speranza, Padua, Italy, University of Padua, Padua, Italy
19 University of Milano-Bicocca, Monza, Italy
20 Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, United States, European Institute of Oncology IRCCS, Milan, Italy, University of Torino, Torino, Italy
21 University of Milano-Bicocca, Monza, Italy
22 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy
23 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, University of Milano-Bicocca, Monza, Italy

Introduction

Anaplastic lymphoma kinase (ALK) rearrangements drive several rare lymphoid malignancies, including ALK-positive anaplastic large-cell lymphoma (ALK+ ALCL), ALK-positive large B-cell lymphoma (ALK+ LBCL), and ALK-positive histiocytosis. Although many patients respond to chemotherapy and first-generation ALK tyrosine kinase inhibitors (TKIs), outcomes after ALK TKI failure remain poor. Lorlatinib, a third-generation ALK/ROS1 TKI with activity against multiple ALK resistance mutations, may overcome resistance to earlier-generation TKIs. To our knowledge, this is the first prospective phase II study evaluating lorlatinib in patients with relapsed/refractory (R/R) ALK-positive lymphoid malignancies after prior ALK TKI failure.

Methods

This phase II, open-label study (NCT03505554) enrolled patients with histologically confirmed R/R ALK-positive lymphoma or ALK-positive histiocytosis previously treated with ≥1 ALK inhibitor. Lorlatinib was administered at 100 mg orally once daily until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR), assessed by 18F-FDG PET according to Lugano criteria (complete metabolic response (CMR) and partial metabolic response (PMR) were considered as responses). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and minimal residual disease (MRD) assessed by RT-PCR for ALK-rearranged transcripts.

Results

Between January 2019 and December 2025, 9 patients were enrolled (median age, 21 years (range, 18-57)): ALK+ LBCL (n=4), ALK+ ALCL (n=4), and ALK-positive histiocytosis (n=1). At a median follow-up of 28 months (range, 1-78), ORR was 100% (95% CI, 66-100). Four patients (44%) achieved CMR after 1 month, all with concomitant RT-PCR negativity. Five patients (56%) achieved PMR; three converted to CMR by month 3, whereas two progressed and died. Five patients subsequently underwent allogeneic hematopoietic stem cell transplantation (allo-SCT), including two in CMR. Two patients in CMR at 1 month decided to postpone allo-SCT and remain in CMR at 78 and 28 months, respectively. Median PFS and OS were not reached; estimated 18-month PFS and OS rates were 75% and 88%, respectively. Early CMR at 1 month together with MRD negativity was associated with improved survival outcomes (P=0.04). Lorlatinib was well tolerated, with predominantly grade 1-2 adverse events (grade 3 hypercholesterolemia occurred in one patient).

Conclusions

Lorlatinib demonstrated high and durable antitumor activity with a favorable safety profile in patients with R/R ALK-positive lymphoid malignancies after prior ALK TKI therapy. Early metabolic response by 18F-FDG PET combined with MRD assessment by RT-PCR may identify patients most likely to achieve sustained remission and help guide decisions regarding treatment consolidation. Further and larger studies are warranted.

Andrea Aroldi, MD: No relevant conflicts of interest to declare.